Reactions to Provenge Data

28/04/09

â??These results confirm the clinical value of Provenge to prolong survival in patients with advanced prostate cancer,â? said Dr. Philip Kantoff, head of the prostate cancer program and chief of the division of solid tumor oncology at the Dana-Farber Cancer Institute and Harvard Medical School, and a principal investigator of the Provenge study, in a [...] (Source: psa-rising.com/blog)

Original post by psa-rising.com/blog and software by Elliott Back

 

No Comments »

No comments yet.

RSS feed for comments on this post. TrackBack URL

Leave a comment

You must be logged in to post a comment.